DiaMedica Therapeutics, Inc. (NASDAQ:DMAC – Free Report) – HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for shares of DiaMedica Therapeutics in a research report issued to clients and investors on Tuesday, August 11th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.20) per share for the quarter, up from their previous forecast of ($0.21). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.80) EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at ($0.60) EPS, FY2029 earnings at ($0.27) EPS and FY2030 earnings at ($0.01) EPS.
DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01.
View Our Latest Stock Report on DMAC
DiaMedica Therapeutics Stock Performance
NASDAQ:DMAC opened at $6.84 on Thursday. DiaMedica Therapeutics has a one year low of $4.90 and a one year high of $10.42. The business’s 50-day simple moving average is $6.66 and its 200 day simple moving average is $6.93. The stock has a market cap of $368.54 million, a price-to-earnings ratio of -9.50 and a beta of 1.01.
Hedge Funds Weigh In On DiaMedica Therapeutics
Hedge funds have recently bought and sold shares of the company. Millennium Management LLC acquired a new position in shares of DiaMedica Therapeutics in the 3rd quarter worth approximately $8,157,000. Geode Capital Management LLC raised its position in shares of DiaMedica Therapeutics by 7.4% during the 4th quarter. Geode Capital Management LLC now owns 764,255 shares of the company’s stock valued at $6,085,000 after acquiring an additional 52,437 shares in the last quarter. State Street Corp raised its position in shares of DiaMedica Therapeutics by 31.7% during the 4th quarter. State Street Corp now owns 627,771 shares of the company’s stock valued at $4,997,000 after acquiring an additional 151,188 shares in the last quarter. Royal Bank of Canada lifted its stake in DiaMedica Therapeutics by 46,879.1% during the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock worth $588,000 after purchasing an additional 154,701 shares during the last quarter. Finally, Osaic Holdings Inc. lifted its stake in DiaMedica Therapeutics by 374.7% during the second quarter. Osaic Holdings Inc. now owns 144,290 shares of the company’s stock worth $563,000 after purchasing an additional 113,893 shares during the last quarter. 10.12% of the stock is currently owned by institutional investors and hedge funds.
About DiaMedica Therapeutics
DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.
DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.
Featured Articles
- Five stocks we like better than DiaMedica Therapeutics
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
